Harvest One Executing on Brands and Distribution Strategy
Ryan Allway
March 27th, 2019
Exclusive, News, Top News
The nature of the compelling stories in the cannabis industry has changed over the last few years. Remember when a late-stage ACMPR applicant was all the rage? Then it was production expansion and funded capacity. Now, all of that potential is turning to the reality of any market – who can sell product and generate revenue?
One company that is making that turn in fine form is Harvest One Cannabis Inc. (TSX-V: HVT) (OTCQX: HRVOF). After building the foundation of a diverse cannabis company with capabilities, both domestically and internationally, in medical, recreational, and nutraceutical markets, Harvest One has launched into the execution phase of its plan. Appointed in July 2018, CEO Grant Froese is utilizing his extensive retail and business management expertise gained over a 30+ year career at Loblaw Companies Ltd. to lead the company with a comprehensive brand and distribution strategy.
Please click here to receive an investor presentation and corporate updates
Harvest One History
Harvest One’s Licensed Producer subsidiary, United Greeneries, was awarded its first license, to cultivate, in Canada in 2016. The company focuses on indoor cannabis production, featuring two premium brands: Captain’s Choice and Royal High. United Greeneries has distribution agreements in place with four provinces and anticipates reaching supply levels of 20,000 kg/yr by the end of 2019 through its fully funded expansions. The company does not intend to scale up in an attempt to compete with larger producers, focusing instead on the premium niche and on more profitable development of derivative products for medical, recreational, and nutraceutical markets.
Still, it’s worth mentioning that Harvest One’s Q2 2019 financials reflect the success of United Greeneries’ brands. Net revenue came in at $3.7 million for the quarter, reflecting a 123% increase over the previous quarter due in large part to initial shipments of premium cannabis under the supply agreements with British Columbia, Saskatchewan, Manitoba, and Ontario. Gross margins came in at a healthy 53% for United Greeneries’ products. These revenues are in line with some of the larger Canadian LP’s.
Another Harvest One subsidiary, Satipharm, was established in 2015 as the medicinal and wellness division of the company. Headquartered in Dublin, Ireland, Satipharm develops and sells cannabinoid-based products which are currently manufactured in a GMP-certified facility in Switzerland. Utilizing its Gelpell® technology to boost bioavailability and ensure consistent dosage, the company is now distributing CBD 10mg Gelpell® capsules in many European countries. Satipharm products are also sold in Australia, one of the first brands to be approved in that emerging medical cannabis market.
In a sure sign of Harvest One’s comprehensive approach to the medical and nutraceutical markets, Satipharm’s Gelpell® formulations have been tested in two clinical trials by another of the company’s subsidiaries, Israeli-based Phytotech Therapeutics. One trial proved that Gelpell® technology increased the bioavailability of CBD, and the other showed promising results in the treatment of pediatric epilepsy.
In 2018, Harvest One acquired Dream Water, another major subsidiary. Dream Water is distributed widely to large retailers throughout North America, offering sleep and beauty aids in the form of all-natural liquid shots and powders.
Please click here to receive an investor presentation and corporate updates
Executing the Plan
With the foundation described above, Mr. Froese was brought on to unify and execute a comprehensive international brand and distribution strategy. A review of recent developments shows Harvest One doing just that.
For the medical market, regardless of jurisdiction, Harvest One is uniting all products under the Satipharm brand. The company’s recent supply agreement with Shoppers Drug Mart is a prime example of how it works. United Greeneries provides the flower product in a number of varieties, and those varieties are marketed using Satipharm’s color-coded system indicating THC/CBD content levels.
Three days after the initial announcement, the first shipment was completed, and the first two varieties are already available through Shoppers’ cannabis web portal.
In November, 2018, Harvest One entered into an agreement with Valens GroWorks, a leader in cannabis extraction and derivative product development. United Greeneries supplies the flower, Valens extracts the resin and oils, and Valens helps Harvest One develop products like beverages, vape pens, nutraceuticals, and personal care products based on the extracted oils.
With Canada set to legalize derivative products later in 2019, and many US markets already showing that derived products are extremely popular with a diverse set of consumers, Harvest One is positioned to capitalize on the highest value segments of the cannabis market. The company already has plans to introduce a CBD version of Dream Water where legal, and with more than 30,000 storefronts throughout North America currently carrying Dream Water it is easy to imagine a broad and successful rollout for the new product lines.
In another move that anticipates Canada’s legalization of cannabis-infused products, Harvest One recently agreed to acquire Delivra Corp., makers and distributors of LivRelief™ branded topicals and creams designed to help control pain. Those products feature delivra™ transdermal delivery technology designed to effectively transport active ingredients in a controlled manner through the skin. Harvest One anticipates leveraging both the extensive distribution network and the delivery technology for the successful launch of its own cannabis-derived products once legal.
Please click here to receive an investor presentation and corporate updates
The Sum of the Parts
Harvest One is an international cannabis house of brands, backed by scientific product development that adheres to the strictest production standards in the world. It has established distribution networks throughout North America, Europe, and Australia. These networks cover not only medical cannabis but consumer-oriented outlets like Walmart, Kroger, and Loblaws, just to name just a few. New management has demonstrated retail sales, marketing, and management experience, and the developments are coming fast and furious.
Investors may come to the Harvest One party for the company’s solid financial footing. They will likely stay for the tremendous upside represented by the execution, currently underway, of its comprehensive international brand and product marketing strategy.
Disclaimer
The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: https://cannabisfn.com/legal-disclaimer/
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
About Ryan Allway
Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.
Search CannabisFN
Press Coverage
Psychedelics Index
Top Videos
Tim has over 22 years of investment experience as a portfolio manager, asset allocator, and capital markets professional across multiple asset classes, geographies, and platforms. Tim has built and operated two hedge funds, a broker dealer, and raised over $1Bn in capital for his combined businesses. Tim remains a recognized voice within the investment community […]
The producers of O’ Cannabiz have decades of experience producing national-profile events and creating global connections between business communities in the arts, broadcasting, media and technology. They have organized trade summit initiatives with governments around the world. And they have worked closely with sponsors in all levels of Canadian government.
Aleafia, a vertically integrated, national cannabis company, operates major medical clinic, cannabis cultivation and R&D facilities.
Revive Therapeutics’ cannabinoid pharmaceutical portfolio focuses on rare inflammatory areas such as liver disease.
Network Partners
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.
Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer
